Todd E. Arnold, Ph.D., currently holds the position of Vice President, Platform Development at panluminate, an early-stage company whose revolutionary innovations in cellular expansion technology will bring unprecedented capability to omics research combining electron microscopy resolution with precise identification of multiple biomarkers at nanometer scale with a light microscope. At panluminate, he is responsible for integrating the panOptiX technology into a robust, customer-focused product line including reagents, protocols, and instrumentation. 
Dr. Arnold was co-founder and Chief Operating Officer of Adela, Incorporated, an early-stage company focused on commercializing technology capable of the detection of cancer and other high-morbidity, high-mortality conditions through a blood test that harnesses the potential of the methylome. Adela’s genome-wide methylation enrichment technology offers the potential to detect many diseases with a single assay. Immediately prior to joining Adela, Dr. Arnold served as the Chief Laboratory Operations Officer for Sema4, a spinout company of the Mount Sinai Health System.  Preceding his role at Sema4, he was the Managing Director of the Mount Sinai Genetic Testing Laboratory—Connecticut and spearheaded the establishment of the state-of-the-art, high throughput nucleic acid sequencing facility. As an active participant in curriculum development at colleges and universities and advocate for bioscience in Connecticut, Dr. Arnold serves on the Workforce Advisory Board for the Professional Science Master's Health Care Genetics Graduate Program at the University of Connecticut, BioPath: the Bioscience Career and Academic Pathway (a partnership between the  City of New Haven and Southern Connecticut State University) Advisory Board, the New Haven Regional Bioscience Collaborative, the Workforce Advisory Board of the National Professional Science Master’s Association, and as Chairman of the Graduate Education Advisory Board at the University of Georgia. 

Previously, Dr. Arnold was the Vice President of Research and Development at 454 Life Sciences, acquired by Roche, where he and his team developed next-generation sequencing instruments, reagents, assays, and software. He earned his B.S. in Biological Sciences from Indiana University, his Ph.D. in Molecular Biology and Genetics from the University of Georgia and was a postdoctoral fellow at Harvard Medical School. He has supported early-stage bioscience companies in Connecticut as a scientific advisor. He was a member of CBIA’s Connecticut Bioscience Growth Council and the Connecticut Health Data Collaborative. He served as a member of the BioCT (the bioscience industry’s voice in the state of Connecticut) Board of Directors and Government Affairs Committee.